Idorsia ' s brain bleed drug flunks PhIII trial, a decade after previous flop

Idorsia’s long journey with clazosentan came to an abrupt “unexpected result” Monday morning with a Phase III flop. The Swiss biopharma said the drug did not meet the main goal of the late-stage REACT study, conducted in the US, Canada and Europe since early 2019. The 409-patient trial tested the…#idorsia
Source: Reuters: Health - Category: Consumer Health News Source Type: news